Newsroom

Immunology

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

August 29, 2024

United States

Oncology

Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress

August 27, 2024

Oncology

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

August 20, 2024

Neuroscience

Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of Medicine

August 7, 2024

United States

Oncology

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible

July 31, 2024

Oncology

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy

July 26, 2024

Neuroscience

Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression

July 22, 2024

United States

Immunology

Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics

NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)

The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases

July 11, 2024

United States

Immunology

Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class

First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADL^a) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+

June 28, 2024

Oncology

CHMP adopts positive opinion for BALVERSA^® (erdafitinib) for the treatment of adult patients

Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers¹

The CHMP’s recommendation is based on results from Cohort 1 of the Phase 3 THOR study, which showed a 36 percent reduction in the risk of death with erdafitinib versus chemotherapy²

June 28, 2024

Newsroom

Press Releases

Discover J&J

Medicines & therapies

Medical devices & technology

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

About us

You are now leaving innovativemedicine.jnj.com

Key links

Get in touch

Search Results

No Results

Recently Viewed

Newsroom

Press Releases

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com

You are now leaving innovativemedicine.jnj.com